Hereditary Spastic Paraplegia and Future Therapeutic Directions: Beneficial Effects of Small Compounds Acting on Cellular Stress
Open Access
- 6 May 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Neuroscience
Abstract
Hereditary spastic paraplegia (HSP) is a group of inherited neurodegenerative conditions that share a characteristic feature of degeneration of the longest axons within the corticospinal tract, which leads to progressive spasticity and weakness of the lower limbs. Mutations of over 70 genes produce defects in various biological pathways: axonal transport, lipid metabolism, endoplasmic reticulum (ER) shaping, mitochondrial function, and endosomal trafficking. HSPs suffer from an adequate therapeutic plan. Currently the treatments foreseen for patients affected by this pathology are physiotherapy, to maintain the outgoing tone, and muscle relaxant therapies for spasticity. Very few clinical studies have been conducted, and it’s urgent to implement preclinical animal studies devoted to pharmacological test and screening, to expand the rose of compounds potentially attractive for clinical trials. Small animal models, such as Drosophila melanogaster and zebrafish, have been generated, analyzed, and used as preclinical model for screening of compounds and their effects. In this work, we briefly described the role of HSP-linked proteins in the organization of ER endomembrane system and in the regulation of ER homeostasis and stress as a common pathological mechanism for these HSP forms. We then focused our attention on the pharmacodynamic and pharmacokinetic features of some recently identified molecules with antioxidant property, such as salubrinal, guanabenz, N-acetyl cysteine, methylene blue, rapamycin, and naringenin, and on their potential use in future clinical studies. Expanding the models and the pharmacological screening for HSP disease is necessary to give an opportunity to patients and clinicians to test new molecules.Funding Information
- Università degli Studi di Padova (PRIDj_018)
- Ministero della Salute
- European Social Fund
- Fondazione Cassa di Risparmio di Padova e Rovigo
This publication has 205 references indexed in Scilit:
- A Conserved Role for Atlastin GTPases in Regulating Lipid Droplet SizeCell Reports, 2013
- Salubrinal attenuates β-amyloid-induced neuronal death and microglial activation by inhibition of the NF-κB pathwayNeurobiology of Aging, 2012
- Glutamatergic medications for the treatment of drug and behavioral addictionsPharmacology Biochemistry and Behavior, 2012
- Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blueProgress in Neurobiology, 2012
- TFG-1 function in protein secretion and oncogenesisNature, 2011
- TOR on the brainExperimental Gerontology, 2011
- Peripheral ER structure and functionCurrent Opinion in Cell Biology, 2009
- A Class of Dynamin-like GTPases Involved in the Generation of the Tubular ER NetworkCell, 2009
- Autophagy in the Pathogenesis of DiseaseCell, 2008
- Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical predictionBritish Journal of Pharmacology, 2007